GlassScriptPhysician profile
Neneth O Phung
NPI 1265597553
$7,193.45
in general payments reported to CMS, 2019-2025
29 companies · $667 in 2025
The $667 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,419 · 2022: $1,793 · 2023: $1,539 · 2024: $1,775 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,331.22 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $1,276.74 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $829.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.31 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $489.92 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $395.52 | 2021-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $306.44 | 2021-2023 | |
| Alkermes, INC. | $274.08 | 2022-2024 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $180.68 | 2021 | |
| Mallinckrodt Hospital Products INC. | $143.06 | 2025 | Terlivaz |
| Lundbeck LLC | $140.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $116.56 | 2023-2025 | Auvelity |
| Sage Therapeutics, LLC | $113.23 | 2024 | |
| Tris Pharma INC | $106.85 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $103.30 | 2024 | Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $87.77 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $77.34 | 2021-2022 | |
| Bausch Health US, LLC | $68.63 | 2021 | |
| Corium, LLC | $53.12 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $48.66 | 2021-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $37.75 | 2021 | |
| Merck Sharp & Dohme LLC | $37.41 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.18 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $32.65 | 2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $30.78 | 2021 | |
| Indivior INC. | $27.02 | 2022 | |
| Neos Therapeutics, LP | $22.40 | 2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neneth Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.